An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

September 6, 2019

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions
Advanced Cancer
Interventions
DRUG

BMS-986288

Specified dose on specified days

DRUG

Nivolumab

Specified dose on specified days

DRUG

Regorafenib

Specified dose on specified days

Trial Locations (40)

1426

Local Institution - 0011, Ciudad Autónoma de Buenos Aires

1431

Local Institution - 0017, Buenos Aires

5800

Local Institution - 0013, Río Cuarto

13915

Local Institution - 0026, Marseille

20133

Local Institution - 0040, Milan

20162

Local Institution - 0031, Milan

21287

Local Institution - 0002, Baltimore

28041

Local Institution - 0023, Madrid

28222

Local Institution - 0024, Majadahonda

33075

Local Institution - 0034, Bordeaux

35128

Local Institution - 0038, Padua

41013

Local Institution - 0055, Seville

44800

Local Institution - 0022, Saint-Herblain

46026

Local Institution - 0025, Valencia

60126

Local Institution - 0028, Ancona

63110

Local Institution - 0004, St Louis

69677

Local Institution - 0018, Bron

75248

Local Institution - 0015, Paris

80045

Local Institution - 0005, Aurora

83100

Centre Hospitalier intercommunal de Toulon La Seyne sur Mer, Toulon

88100

Local Institution - 0033, Catanzaro

92627

Local Institution - 0075, Costa Mesa

2520598

Local Institution - 0010, Viña del Mar

7500921

Local Institution - 0036, Santiago

7510032

Local Institution - 0019, Santiago

7620002

Local Institution - 0035, Santiago

8420383

Local Institution - 0009, Santiago

92868-3201

Local Institution - 0050, Orange

07601

Local Institution - 0001, Hackensack

C1096AAS

Local Institution - 0074, Buenos Aires

X5000HXL

Local Institution - 0014, Córdoba

C1199

Local Institution - 0008, ABB

C1430

Local Institution - 0012, CABA

C1280AEB

Local Institution - 0016, Buenos Aires

M5G 2M9

Local Institution - 0006, Toronto

H2X 0A9

Local Institution - 0042, Montreal

H3T 1E2

Local Institution - 0046, Montreal

00168

Local Institution - 0039, Roma

08035

Local Institution - 0056, Barcelona

08036

Local Institution - 0054, Barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03994601 - An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers | Biotech Hunter | Biotech Hunter